613-77-4

Usage

Uses

Used in Pharmaceutical Industry:
2,7-dichloroquinoline is used as a precursor for the synthesis of various compounds in the pharmaceutical industry. Its chemical structure allows for the creation of a wide range of derivatives with potential therapeutic applications.
Used in Chemical Synthesis:
2,7-dichloroquinoline is used as a building block in the synthesis of complex organic molecules. Its reactivity and versatility make it a valuable component in the development of new chemical entities with potential applications in various fields, including materials science and agrochemistry.
Used in Research and Development:
2,7-dichloroquinoline is employed as a research compound in academic and industrial laboratories. It serves as a model system for studying the properties and reactivity of quinolines and their derivatives, contributing to the advancement of organic chemistry and related fields.

InChI:InChI=1/C9H5Cl2N/c10-7-3-1-6-2-4-9(11)12-8(6)5-7/h1-5H

Upstream product

• 22614-72-8 7-chloroquinolin-2-ol 
• 445041-60-1 (E)-N-(3-chlorophenyl)-3-ethoxypropenamide 
• 22614-72-8 7-chloroquinolin-2(1H)-one 
• 156820-88-1 4,7-dichloro-quinolin-2-ol 

Downstream Products

• 5443-04-9 N⁴,N⁴-diethyl-N¹-(7-chloro-[2]quinolyl)-1-methyl-butanediyldiamine 
• 143816-79-9 7-chloro-2-<(3-methoxyphenyl)thio>quinoline 
• 445041-74-7 (R)-(+)-2-{4-[(7-chloro-2-quinolinyl)oxy]phenoxy}propionic acid 
• 43200-95-9 2-amino-7-chloroquinoline 
• 143816-81-3 methyl D,L-2-<3-<(7-chloroquinolinyl)thio>phenoxy>propanoate 
• 143816-63-1 2-[3-(7-Chloro-quinolin-2-ylsulfanyl)-phenoxy]-propionic acid 
• 143816-80-2 7-chloro-2-<(3-hydroxyphenyl)thio>quinoline 

Relevant academic research and scientific papers

2-(4-Alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists

With the aim of identifying structurally novel, centrally acting histamine H3 antagonists, a series of 2-(4-alkylpiperazin-1-yl)quinolines was prepared. Systematic variation of the substituents led to highly potent histamine H3 antagonists with low polar surface area and appropriate log P for blood-brain barrier penetration.

II. Synthesis and biological evaluation of some bioisosteres and congeners of the antitumor agent, 2-{4-[(7-chloro-2-quinoxalinyl)oxylphenoxy}propionic acid (XK469)

XK469 (1) is among the most highly and broadly active antitumor agents to have been evaluated in our laboratories. Subsequent developmental studies led to the entry of (R)-(+) 1 (NSC 698215) into phase 1 clinical trials (NIH UO1-CA62487). The antitumor me

Development of a novel series of styrylquinoline compounds as high- affinity leukotriene D4 receptor antagonists: Synthetic and structure- activity studies leading to the discovery of (±)-3-[[[3-[2-(7-chloro-2- quinolinyl)-(E)-ethenyl]phenyl][[3-(dimethylamino)-3- oxopropyl]thio]methyl]thio]propionic acid

Based on LTD4 receptor antagonist activity of 3-(2-quinolinyl-(E)- ethenyl)pyridine (2) found in broad screening, structure-activity studies were carried out which led to the identification of 3-[[[3-[2-(7-chloro-2- quinolinyl)-(E)-ethenyl]phenyl][[3-(dimethylamino)-3- oxopropyl]thio]methyl]thio]propionic acid (1, MK-571) as a potent and orally active LTD4 receptor antagonist. These studies demonstrated that a phenyl ring could replace the pyridine in 2 without loss of activity, that 7-halogen substitution in the quinoline group was optimal for binding, that the (E)- ethenyl linkage was optimal, that binding was enhanced by incorporation of a polar acidic group or groups in the 3-position of the aryl ring, and that two acidic groups could be incorporated via a dithioacetal formed from thiopropionic acid and the corresponding styrylquinoline 3-aldehyde to yield compounds such as 20 (IC50 = 3 nM vs [3H]LTD4 binding to the guinea pig lung membrane). It was found that one of the acidic groups could be transformed into a variety of the amides without loss of potency and that the dimethylamide 1 embodied the optimal properties of intrinsic potency (IC50 = 0.8 nM on guinea pig lung LTD4 receptor) and oral in vivo potency in the guinea pig, hyperreactive rat, and squirrel monkey. The evolution of 2 to 1 involves the increase of >6000-fold in competition for [3H]LTD4 binding to guinea pig lung membrane and a >40-fold increase in oral activity as measured by inhibition of antigen-induced dyspnea in hyperreactive rats.

1,4-Dithiino(2,3-c)pyrrole derivatives

New compounds of the formula: SPC1 Wherein A is a phenyl, pyridyl, pyridazinyl, 2-, 3- or 4-quinolyl or naphthyridinyl radical, or a said radical substituted by one or two atoms or radicals selected from halogen, alkyl, alkoxy cyano and nitro, R is alkyl, alkenyl or hydroxyalkyl, and n is zero or 1, possess pharmacological properties and are, in particular, active as tranquilisers, anti-convulsant agents, decontracturants and agents to produce hypnosis.